Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06378138
Status:
RECRUITING
Last Update Posted:
2024-04-22
First Post:
2024-04-06
Brief Title:
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Sponsor:
Beijing InnoCare Pharma Tech Co Ltd
Organization:
Beijing InnoCare Pharma Tech Co Ltd
Study Overview
Official Title:
A Phase IIIII Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the safety tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None